Clinical Trial

A Prospective Low-interventional Phase 4 Single Arm Study Of Ocular Assessments In Patients Treated With Tivdak® In Recurrent Or Metastatic Cervical Cancer

MOA: Tisotumab vedotin-tftv (Tivdak®) is a tissue factor (TF)-directed ADC with an MMAE payload.

Key Eligibility:

• Recurrent/metastatic cervical cancer with PD on/after
  chemotherapy
• Tivdak recommended by physician according to US prescribing
  information
• Must be willing to undergo repeated ocular assessments
• Pts with active ocular disease at baseline are excluded
• Previous treatment with Tivdak is excluded
• Prior tx with an investigational drug within 30 days is excluded
• Pts are advised to avoid wearing contact lenses for the entire
  duration of therapy